CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
CTS will be revising some forms in use by clients on October 26, 2020. We do try to limit form chang...
Daylight Saving Time Begins March 10, 2019. As a friendly reminder, airlines often change their rout...
Reminder: On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the ch...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...